Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...

Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most often in children and young adults. In recent years, CAR-T cell therapy—often ...

Integration of targeted therapies and immunotherapies offers new hope, enhancing survival rates and quality of life. Patients with mantle cell lymphoma experienced better survival rates when treated ...

What Is Marginal Zone Lymphoma? Marginal zone lymphoma (MZL) isn’t one disease. It’s a group of rare, slow-growing blood cancers. They’re known as non-Hodgkin lymphomas because they start in your ...

The Global Mantle Cell Lymphoma Market offers significant growth potential driven by an aging population increasing cancer prevalence and the success of targeted oral drugs and immunotherapies. Rapid ...

The FDA has granted full approval to verdinexor tablets (Laverdia; Anivive Lifesciences) for the treatment of dogs with lymphoma. The approval gives veterinarians a promising new oral avenue for ...